Navigation Links
Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
Date:3/24/2008

developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.celltherapeutics.com.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with pixantrone in particular including, without limitation, the potential failure of pixantrone to prove safe and effective for treatment of relapsed aggressive NHL, determinations by regulatory, patent and administrative governmental authorities that the PIX301 trial is insufficient to demonstrate pixantrone's safety and effectiveness for commercial use, competitive factors, technological developments, costs of developing, producing and selling pixantrone,, and the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by Italian law, CTI is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

Media Contact:

Dan Eramian

T: 206.272.4343

C: 206.854.1200

Susan Callahan

T: 206.272.4472

F: 206.272.4434

E: media@ctiseattle.com

http://www.cticseattle.com/media.htm

Investors Contact:

Leah Grant

T: 206.282.7100

F: 206.272.4434

'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dynamis Therapeutics, Inc. Discovers RAGE Inhibitor
2. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
3. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
4. Ocera Therapeutics, Inc. Completes Enrollment in FHAST1, a Pivotal Phase 3 Clinical Trial in Fistulizing Crohns Disease
5. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
6. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
7. Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
8. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
9. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
10. IDM Pharma Announces Availability of Mifamurtide (L-MTP-PE) Through Compassionate Access Study
11. Valor Medical Announces First Human Implant of Neucrylate AN(TM) for Treatment of Cerebral Aneurysm
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  CytoSorbents Corporation (NASDAQ ... its CytoSorb® extracorporeal cytokine adsorber to reduce deadly ... the receipt of $385,642, net of transaction costs, ... the Technology Business Tax Certificate Transfer Program sponsored ...
(Date:1/22/2015)... CLEVELAND , Jan. 22, 2015  ViewRay™, a privately ... entered into an exclusive distributor agreement with ITOCHU Corporation ... radiation therapy system for the treatment of cancer in ... (me-rid-i-an) system, is the world,s first and only MRI-guided ...
(Date:1/22/2015)... (NASDAQ: AMGN ) today announced that it will report ... Jan. 27, 2015, after the close of the U.S. financial markets. ... investment community at 2 p.m. PT. Participating in the call from ... executive officer, and other members of Amgen,s senior management team. ...
Breaking Medicine Technology:CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2Amgen Announces Webcast of 2014 Fourth Quarter and Full Year Financial Results 2
... YORK, Oct. 30 See video ... Novartis announced that the US ... (everolimus) tablets for patients with subependymal giant cell ... tuberous sclerosis (TS), who require therapeutic intervention but ...
... BioMedix announced today that TRAKnet Practice Management Software 2.0 ... Complete EHR on October 28th, 2010 by the ... in accordance with the applicable Eligible Provider certification criteria ... The 2011/2012 criteria support the Stage 1 meaningful use ...
Cached Medicine Technology:BioMedix's TRAKnet Practice Management Software Receives ONC-ATCB 2011/2012 Certification 2BioMedix's TRAKnet Practice Management Software Receives ONC-ATCB 2011/2012 Certification 3BioMedix's TRAKnet Practice Management Software Receives ONC-ATCB 2011/2012 Certification 4
(Date:1/22/2015)... AngelWeddingDress, the premier women’s dress supplier, has recently released ... website of AngelWeddingDress.com to find more details. , ... for a bridal party. AngelWeddingDress offers a variety of ... maternity wedding dresses are specially designed for 2015. , ...
(Date:1/22/2015)... Autocarinsurancebest.com has released a new blog post ... insurance policy . , Auto insurance quotes help many ... no longer necessary to call an agent or visit an ... on a single website: http://autocarinsurancebest.com/ . , Every business ...
(Date:1/22/2015)... 22, 2015 Yesterday, Senator Holly ... and Kristin Olsen (R-Modesto) were honored by the ... advancing biotechnology, biomedical science, medical device and pharmaceutical ... received the “2014 Life Sciences Champion” award from ...
(Date:1/22/2015)... EBSCO Information Services (EBSCO) and the ... an effort to further promote visibility and adoption of the ... made AMA journals available via its subscription services, EBSCO will ... , Long known as both a subscription agency ...
(Date:1/22/2015)... 2015 Step into a macabre world ... Museum of Virginia. Wicked Plants, the Museum’s latest featured ... 75 poisonous, carnivorous and diabolical plants inside of a ... uncover the biochemical, physical and neurological processes between botanicals ...
Breaking Medicine News(10 mins):Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4Health News:Wicked Plants are taking over the Science Museum of Virginia 2
... , NEW YORK, Sept. 10 , , , What: ... Americans could come down with the swine flu this fall and, ... by July, more, than a ... hospitalized. With fears that swine flu will become a, ...
... , , ST. LOUIS, ... management, business intelligence and performance management solutions announced that ... portal for BlueAdvantage Administrators of Arkansas to enable greater ... The intranet portal will provide BlueAdvantage employees the ability ...
... OIG Report Indicates Attention to Compliance Issues is ... 10 Yesterday, the Department of Health and Human Services Office ... series of four, which reviewed the hospice benefit for residents of ... claims that were part of the study did not meet at ...
... , , KANSAS CITY, Mo., Sept. 10 ... a treatment and cure for polycystic kidney disease (PKD), a genetic ... may be put on hold if fundraising efforts continue to fall ... event. , , The Walk for PKD, held ...
... , , , ... :PRX) today announced that it has received final approval from the ... for nateglinide tablets. Nateglinide is a generic version of Novartis, ... according to IMS Health data. Par will begin shipping the ...
... In the news release, "First Results From Major European ... issued on 9,Sep 2009 07:00 GMT, by Nycomed over PR ... the first set of bullet points should read,"The median number ... episode,had a median duration of 60 minutes; 96% of the ...
Cached Medicine News:Health News:Insite Security Hosts Webinar on Swine Flu Preparedness 2Health News:Amitech Solutions Selected to Implement SharePoint Portal for BlueAdvantage Administrators of Arkansas 2Health News:Amitech Solutions Selected to Implement SharePoint Portal for BlueAdvantage Administrators of Arkansas 3Health News:NHPCO Working to Help Hospices With Compliance for Hospice Patients in Nursing Homes 2Health News:NHPCO Working to Help Hospices With Compliance for Hospice Patients in Nursing Homes 3Health News:Success of National Fundraising Event Critical to Promising Research for Life-Threatening Kidney Disease 2Health News:Par Pharmaceutical Receives Final Approval To Market Generic Starlix(R) 2Health News:/C O R R E C T I O N -- Nycomed/ 2Health News:/C O R R E C T I O N -- Nycomed/ 3Health News:/C O R R E C T I O N -- Nycomed/ 4Health News:/C O R R E C T I O N -- Nycomed/ 5Health News:/C O R R E C T I O N -- Nycomed/ 6Health News:/C O R R E C T I O N -- Nycomed/ 7
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: